Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06932263 · ClinicalTrials.gov registry record · Phase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
A Phase 2 study of Asthma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT06932263: Recruiting Phase 2 study of Asthma, sponsored by AstraZeneca.
NCT06932263 is a Phase 2 study of Asthma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 540 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06932263, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Primary Outcome
The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and ≥ 1 severe exacerbation within 12 months prior to screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tozorakimab
Study Locations (20)
Florida
- Research Site - Cutler Bay
- Research Site - Hialeah
- Research Site - Hialeah
- Research Site - Leesburg
- Research Site - Miami
- Research Site - Miami
- Research Site - Orlando
- Research Site - Palmetto Bay
- Research Site - Tampa
- Research Site - Winter Park
California
- Research Site - Bakersfield
- Research Site - Huntington Beach
- Research Site - La Mesa
- Research Site - Newport Beach
- Research Site - San Jose
Delaware
- Research Site - Wilmington
Idaho
- Research Site - Boise
Indiana
- Research Site - Indianapolis
Iowa
- Research Site - West Des Moines
Kentucky
- Research Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2028-03-16 |
| Phase | Phase 2 |
What NCT06932263 shows while recruiting
NCT06932263 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06932263 names 20 study sites across 7 states, led by Florida, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT06932263 about?
NCT06932263 is a clinical study titled "Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids". This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
What is the current status of trial NCT06932263?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 540 participants. The study started on 2025-03-26. Estimated completion is 2028-03-16.
What conditions does trial NCT06932263 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06932263?
The interventions under investigation include: Placebo (DRUG), Tozorakimab (DRUG).
Who is sponsoring clinical trial NCT06932263?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06932263 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06932263's enrollment target sits among peer trials
540 76th of 374 higher than 299 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI